Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway. - Wang C; Wu Z; Zhou J; Cheng B; Huang Y (Journal of cancer research and clinical oncology, 2025)